An Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303
- Conditions
- Lennox Gastaut Syndrome
- Registration Number
- NCT03778424
- Lead Sponsor
- Eisai Inc.
- Brief Summary
This is an extended access study for participants who have completed Rufinamide Study E2080-G000-303 to continue to have access to rufinamide until it becomes commercially available in Poland or until no participants remain in the EAP.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- AVAILABLE
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Participants who were on rufinamide treatment and have completed Study E2080-G000-303 in Poland.
Exclusion Criteria
- Participants were randomized to the other antiepileptic drug (AED) treatment group in study E2080-G000-303.
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
Generała Tadeusza Kościuszki 52
🇵🇱Kielce, Poland
Szpital Kliniczny im. Heliodora Święcickiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu
🇵🇱Poznań, Poland